23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects

Huang, Huichang; Qian, Xiaohua; Pan, Rong; Shen, Lei; Liang, Shanshan; Wang, Feifei; Zhang, Peng; Shen, Hongbo; Chen, Zheng W.

doi:10.1016/j.clim.2018.05.002

Cited by 3 publications

(3 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most studies (27/39) were cohort studies [5 , 13 . [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , 11/39 studies were RCTs [14 , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , and one study was a combination a cohort study and an RCT [57] . Only 8/39 studies included a HIV negative reference group [27 , 29 , 31 , 34 , [38] , [39] , [40] , 48] .…”

Section: Resultsmentioning

confidence: 99%

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

Background The objective of this systematic review and meta-analysis was to summarise the literature regarding the immunogenicity of pneumococcal conjugate vaccines (PCV) and pneumococcal polysaccharide vaccines (PPSV) in adult people living with HIV (PLWH) in the era of advanced combination antiretroviral therapy (cART). Methods The systematic review protocol was published online (PROSPERO ID: CRD 42020153137). We searched Medline (Ovid), EMBASE (Ovid), and the Global Health Library for publications from 2000 to June 11, 2020. We included all studies in adult PLWH that reported vaccine immunogenicity outcomes. The primary outcome was seroconversion rate (SCR) after PCV, PPSV and PCV/PPSV combined. For random-effects meta-analysis, we included studies defining SCR as a ≥ 2-fold increase in IgG from baseline, and reporting SCR for serotypes 6B, 14, or overall SCR, 1–3 months after vaccination. Findings Our search identified 1597 unique studies, of which 115 were eligible for full-text assessment. Of these, 39 met the inclusion criteria (11 RCTs; 28 cohort studies). A high degree of heterogeneity was observed. Nineteen studies were included in the meta-analysis. Pooled overall SCRs were 42% (95% CI 30–56%), 44% (95% CI 33–55%) and 57% (95% CI 50–63%) for PLWH who received PPSV, PCV or a combination of PCV/PPSV, respectively. Compared to PPSV alone, a combination of PCV/PPSV yielded higher SCRs (OR 2.24 95% CI 1.41- 3.58), whereas we did not observe a significant difference in SCR between PCV and PPSV23 alone. There were no statistically significant differences in geometric mean post-vaccination antibody concentrations between vaccination schedules. Vaccination at higher CD4 cell counts improved immunogenicity in 8/21 studies, especially when PCV was administered. No studies assessed the long-term immunogenicity of PCV followed by PPSV23. Quality of evidence ranged from poor ( n = 19) to good quality ( n = 7). A limited number of pneumococcal serotypes was assessed in the majority of studies. Interpretation We show that the recommended immunisation schedule consisting of a combination of PCV13/PPSV23, is immunogenic in PLWH in the era of advanced cART. However, the durability of this vaccination schedule remains unknown and must be addressed in future research. Vaccination with PCV should be delayed until immunological recovery (CD4>200) in recently diagnosed PLWH for optimal immunogenicity. The evidence gathered here supports wide implementation of the combination of PCV/PPSV23 for all PLWH. We recommend reassessment of this strategy once higher-valent PCVs become available. Funding HMGG is funded by a public research grant of ZonMw (project number 522004005).

show abstract

Section: Resultsmentioning

confidence: 99%

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Our finding that PPV23 response correlates with the level of anti‐αGal may therefore support the perception of an individual capacity for the production of anti‐carbohydrate antibodies. HIV infection is associated with PPV23 hyporesponsiveness by yet incomplete understood mechanisms 24,25 . Thus, to understand the individual capacity for production of anti‐carbohydrate antibodies more generally, it is also important to study the phenomenon in healthy humans as well as humans with other types of immunodeficiencies.…”

Section: Discussionmentioning

confidence: 99%

“…HIV infection is associated with PPV23 hyporesponsiveness by yet incomplete understood mechanisms. 24,25 Thus, to understand the individual capacity for production of anti-carbohydrate antibodies more generally, it is also important to study the phenomenon in healthy humans as well as humans with other types of immunodeficiencies. It may also be of interest to address whether the capacity for generating anti-carbohydrate antibodies is actually distinct from the capacity for generating anti-peptide antibodies.…”

Section: Anti-αgal Level Predicts Ppv23 Response Assessed As Categorical Parametermentioning

confidence: 99%

The level of naturally occurring anti‐αGal antibody predicts antibody response to polysaccharide vaccination in HIV‐infected adults

2020

View full text Add to dashboard Cite

In clinical practice, the capacity for producing anti‐carbohydrate antibodies is regarded as an entity, but supportive evidence is lacking. We hypothesized that the outcome of the gold standard test for clinical assessment of this capacity, antibody response to polysaccharide vaccination, correlated with the level of the abundant naturally occurring anti‐carbohydrate antibody, anti‐αGal. To perform an exploratory study, 47 HIV‐infected adults were recruited from a vaccine trial. Participants received a 23‐valent pneumococcal capsular polysaccharide vaccine. Plasma samples obtained just before and median 4 weeks after the vaccination were quantified for IgG anti‐αGal antibody and IgG antibodies to polysaccharides present in the vaccine (serotypes 1, 7F and 19A) by solid‐phase type immunoassays. The vaccination responses were assessed as a categorical variable (based on criteria defined by The American Academy of Allergy, Asthma & Immunology and the American College of Allergy, Asthma & Immunology) and as three different continuous variables (antibody increment, geometrical average and standard normal deviates of the achieved antibody concentrations). The baseline anti‐αGal level predicted the vaccine response as a categorical variable (ROC‐curve analysis, AUC = 0.71; 95%CI: 0.55‐0.86) and as the three continuous variables (eg slope of linear regression of geometrical average = 0.37; 95%CI: 0.15‐0.59). The correlation between the anti‐αGal level and antibody responses to polysaccharide vaccination fits with a shared underlying capacity. Thus, the present study supports the notion of a measurable capacity for the production of anti‐carbohydrate antibodies in each individual. Firm conclusions on the generalizability and clinical utility require further studies.

show abstract

A System Intervention to Increase Pneumococcal Vaccination Rates in Adults Living With Human Immunodeficiency Virus Who Present for Scheduled Medical Care

Jensen,

Waldrop,

Derouin

et al. 2024

J Assoc Nurses AIDS Care

View full text Add to dashboard Cite

Pneumococcal vaccinations are recommended for adults living with HIV; however, eligibility criteria are complex. At a clinic specializing in the care of lesbian, gay, bisexual, transgender, or queer/questioning persons, only 36% of patients who were vaccine-eligible received the vaccination. A set of decision trees was developed to guide clinic personnel in determining whether a vaccine is recommended. The provider then determined whether the vaccine was appropriate based on each patient's complete clinical presentation. When appropriate, patients were offered the vaccine at the same appointment. This practice change led to a 22% increased vaccination rate.

show abstract

23-valent pneumococcal polysaccharide vaccine elicits hierarchical antibody and cellular responses in healthy and tuberculosis-cured elderly, and HIV-1-infected subjects

Cited by 3 publications

References 42 publications

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis

Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis

The level of naturally occurring anti‐αGal antibody predicts antibody response to polysaccharide vaccination in HIV‐infected adults

A System Intervention to Increase Pneumococcal Vaccination Rates in Adults Living With Human Immunodeficiency Virus Who Present for Scheduled Medical Care

Contact Info

Product

Resources

About